Free Trial
NASDAQ:OMCL

Omnicell (OMCL) Stock Price, News & Analysis

Omnicell logo
$35.46 +0.20 (+0.57%)
Closing price 04/2/2025 04:00 PM Eastern
Extended Trading
$34.66 -0.80 (-2.26%)
As of 04:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Omnicell Stock (NASDAQ:OMCL)

Key Stats

Today's Range
$34.06
$35.51
50-Day Range
$32.28
$45.31
52-Week Range
$25.12
$55.75
Volume
319,583 shs
Average Volume
515,404 shs
Market Capitalization
$1.66 billion
P/E Ratio
131.34
Dividend Yield
N/A
Price Target
$51.00
Consensus Rating
Hold

Company Overview

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. It also provides central pharmacy automation solutions; IV compounding robots; and inventory management software. In addition, the company provides single-dose automation solutions that fill and label a variety of patient-specific, single-dose medication blister packaging based on incoming prescriptions; fully automated and semi-automated filling equipment for institutional pharmacies to warrant automated packaging of medications; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Fort Worth, Texas.

Remove Ads

Omnicell Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

OMCL MarketRank™: 

Omnicell scored higher than 62% of companies evaluated by MarketBeat, and ranked 392nd out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Omnicell has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Omnicell has only been the subject of 4 research reports in the past 90 days.

  • Read more about Omnicell's stock forecast and price target.
  • Earnings Growth

    Earnings for Omnicell are expected to grow by 13.76% in the coming year, from $1.09 to $1.24 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Omnicell is 131.34, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 22.54.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Omnicell is 131.34, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 23.12.

  • Price to Earnings Growth Ratio

    Omnicell has a PEG Ratio of 7.53. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Omnicell has a P/B Ratio of 1.32. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Omnicell's valuation and earnings.
  • Percentage of Shares Shorted

    3.64% of the float of Omnicell has been sold short.
  • Short Interest Ratio / Days to Cover

    Omnicell has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Omnicell has recently decreased by 10.38%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Omnicell does not currently pay a dividend.

  • Dividend Growth

    Omnicell does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    3.64% of the float of Omnicell has been sold short.
  • Short Interest Ratio / Days to Cover

    Omnicell has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Omnicell has recently decreased by 10.38%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Omnicell has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Omnicell this week, compared to 5 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Omnicell insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.64% of the stock of Omnicell is held by insiders.

  • Percentage Held by Institutions

    97.70% of the stock of Omnicell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Omnicell's insider trading history.
Receive OMCL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Omnicell and its competitors with MarketBeat's FREE daily newsletter.

OMCL Stock News Headlines

Omnicell appoints Perry Genova as new CTO
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
StockNews.com Downgrades Omnicell (NASDAQ:OMCL) to Hold
Omnicell price target lowered to $36 from $44 at JPMorgan
Omnicell, Inc. (OMCL) Stock Forecasts
See More Headlines

OMCL Stock Analysis - Frequently Asked Questions

Omnicell's stock was trading at $44.52 on January 1st, 2025. Since then, OMCL stock has decreased by 20.4% and is now trading at $35.46.
View the best growth stocks for 2025 here
.

Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings results on Thursday, February, 6th. The company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.57 by $0.12. Omnicell had a trailing twelve-month return on equity of 3.82% and a net margin of 1.13%.

The following companies are subsidiaries of Omnicell: MarkeTouch Media LLC, ReCept Pharmacy, FDS Amplicare, 340B Link Business, InPharmics, Ateb Inc., Aesynt, and others.

Shares of OMCL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Omnicell investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), Broadcom (AVGO) and Palo Alto Networks (PANW).

Company Calendar

Last Earnings
2/06/2025
Today
4/02/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Electronic computers
Sub-Industry
Health Care Technology
Current Symbol
NASDAQ:OMCL
Employees
3,800
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$51.00
High Stock Price Target
$64.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+43.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
131.34
Forward P/E Ratio
32.53
P/E Growth
7.53
Net Income
$12.53 million
Pretax Margin
2.30%

Debt

Sales & Book Value

Annual Sales
$1.11 billion
Cash Flow
$2.74 per share
Price / Cash Flow
12.95
Book Value
$26.84 per share
Price / Book
1.32

Miscellaneous

Free Float
45,094,000
Market Cap
$1.66 billion
Optionable
Optionable
Beta
0.85

Social Links

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

This page (NASDAQ:OMCL) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners